Skip to content

Metacrine’s lead drug Fast Track’d for NASH

August 25, 2020

The FDA designates Metacrine’s (MTCR) lead program, MET409 for Fast Track review for the treatment of non-alcoholic steatohepatitis (NASH).

MET409 targets farnesoid X receptor (FXR) a protein which plays a key role in modulating said diseases.

Recently, the company filed for $100M IPO.

https://seekingalpha.com/news/3608760-metacrine-lead-drug-fast-trackd-for-nash

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: